Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Anticancer Res
; 35(12): 6941-50, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-26637920
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Receptor, ErbB-2
/
Bevacizumab
Type of study:
Clinical_trials
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Anticancer Res
Year:
2015
Type:
Article
Affiliation country:
Spain